Group 1 - Shenzhen Pumen Technology Co., Ltd. has recently obtained IVDR CE certification for seven electrochemiluminescence reagent products from T?V S?D Group, which is a significant achievement for the company [1] - The certified products include various prostate-specific antigen kits and other diagnostic assays, which are intended for cancer screening, diagnosis, and monitoring [1] - With the new EU In Vitro Diagnostic Medical Devices Regulation (IVDR), the company has now a total of 27 electrochemiluminescence reagent products certified, enhancing its competitiveness in the EU market [1] Group 2 - The IVDR CE certification allows the company’s products to enter the EU market, which is expected to positively impact the company's future operations [1]

近日，深圳普门科技股份有限公司（以下简称"公司"）的 7 项电化学发 光试剂产品获得欧盟公告机构 TÜV 南德意志集团签发的 IVDR CE 认证。具体 情况如下： 证券代码：688389 证券简称：普门科技 公告编号：2025-058 深圳普门科技股份有限公司 关于自愿披露公司产品获得IVDR CE认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据欧盟体外诊断医疗器械法规的规定，本次获得 IVDR CE 认证的产品已 经具备进入欧盟市场的必要条件，有利于进一步提升公司体外诊断产品在欧盟 市场的综合竞争力，对公司未来的经营将产生积极影响。 三、风险提示 本次获得 IVDR CE 认证，仅代表公司相关产品获得欧盟市场的准入资格， 产品的实际销售情况取决于未来市场的推广效果，目前尚无法预测其对公司未 来业绩的具体影响。敬请投资者理性投资，注意投资风险。 特此公告。 深圳普门科技股份有限公司董事会 2025年7月23日 2 / 2 | 序 | 产品名称 | 分类 | 证书 | 预期用途 | | --- | --- ...

Core Insights - The company, Pumen Technology, has recently announced that seven of its electrochemical luminescent reagent products have received IVDR CE certification from the EU Notified Body T V Süddeutsche Gruppe [1] Group 1 - The certification indicates compliance with European regulations for in vitro diagnostic medical devices, enhancing the company's marketability in the EU [1] - This achievement may open new opportunities for the company in the European market, potentially increasing sales and market share [1] - The certification process reflects the company's commitment to quality and regulatory standards in the healthcare industry [1]

Group 1 - The core viewpoint of the news highlights that DingSa Investment has conducted research on a listed company, focusing on its recent product developments and market strategies [1] - Pumen Technology has received CE certification for its fully automated chemiluminescence immunoassay analyzers eCL8600 and eCL8800, which are now available in international markets, enhancing the company's competitiveness in the global in vitro diagnostics sector [1] - The mid-speed luminescence products are designed to meet the needs of secondary hospitals in China, aiming to serve the basic healthcare market [1] Group 2 - In June, Pumen Technology's carbon dioxide laser treatment machine obtained domestic Class III medical device registration, indicating its capability to treat various skin conditions and its unique position in the aesthetic medical device market [1] - The company plans to continue investing in research and development to expand its portfolio of optical aesthetic medical products, aligning with consumer demands [1] - DingSa Investment, established in March 2012, has a strong track record in asset management and has received multiple awards for its performance in the private equity sector [2]

Core Insights - The article discusses the phenomenon of "middlemen profiting" in the innovative drug industry, highlighted by the strategic collaboration between BMS and BNT, which involved a $9 billion deal for the drug BNT327, originally licensed from Chinese company Pumice Biotech [1][2] - The rapid increase in valuations and the perceived undervaluation of Chinese biotech firms are emphasized, with examples illustrating how companies like Pumice and Hengrui have faced challenges in capturing the full value of their innovations [1][2][3] Summary by Sections Strategic Collaborations - BMS and BNT's partnership to develop BNT327 is valued at $9 billion, with Pumice Biotech originally licensing the drug for $55 million [1] - Hengrui Pharmaceuticals licensed its asthma drug SHR-1905 to Aiolos Bio for $25 million upfront, which was later sold to GSK for $10 billion, showcasing the significant markup in valuations [2] Market Dynamics - The article highlights the immature valuation system for innovative drug companies in China and their limited international operational capabilities, leading to unfavorable deals [2][3] - The quality of clinical data and the lack of unique assets hinder Chinese companies' bargaining power in the global market [3] Evolution of BD Transactions - The evolution of business development (BD) transactions in China is outlined, with three phases: exploration (pre-2014), development (2015-2019), and explosion (2020-present) [4][5] - The surge in BD transactions is attributed to the establishment of numerous innovative drug companies post-2010 and regulatory changes that encouraged innovation [5][6] License-in and License-out Trends - License-in transactions dominated initially, allowing companies to mitigate risks and shorten development timelines, but led to inflated prices and market bubbles [6][7] - License-out transactions have recently surpassed License-in, indicating a shift in strategy as companies seek immediate cash flow amid financial pressures [8] New Business Models - The emergence of the NewCo model allows companies to retain longer-term control over their product pipelines while attracting investment, marking a shift from traditional licensing agreements [13][14] - The NewCo model has gained traction among various biotech firms, enabling them to better manage their assets and secure funding [13][15] Future Outlook - The article concludes that while "cheap sales" of assets may continue, Chinese biotech firms are increasingly integrating into the global ecosystem, necessitating a focus on maximizing value within the international value chain [15][16]

Group 1 - The core business of the company includes research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The company achieved a revenue of 215 million yuan in Q1 2025, representing a year-on-year decrease of 29.69%, and a net profit of 53.68 million yuan, down 49.93% year-on-year, with a gross profit margin of 64.97% [2] - The company has received multiple awards, including the "Smart Health Elderly Care Application Pilot Demonstration Enterprise" honor and the "2023 China Corrosion and Protection Society Science and Technology Award" [2] Group 2 - The company's current price-to-earnings (PE) ratio is 19.22, which is significantly lower than the industry average of 51.58 and the industry median of 37.46 [3] - The total market capitalization of the company is 5.609 billion yuan [1] - As of Q1 2025, there are 7 institutions holding shares in the company, with a total holding of 39.11 million shares valued at 588 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Shangrong Medical, which has a current PE ratio of 150.86, significantly higher than the industry average of 51.42 [1][2] - As of July 7, Shangrong Medical's stock closed at 3.99 yuan, marking a 2.57% increase, with a total market capitalization of 3.374 billion yuan [1] - The company has seen a net inflow of 10.55 million yuan in principal funds on July 7, with a total inflow of 9.69 million yuan over the past five days [1] Group 2 - Shangrong Medical reported a revenue of 280 million yuan for Q1 2025, reflecting a year-on-year increase of 30% [2] - The net profit for the same period was 13.96 million yuan, showing a year-on-year growth of 0.58%, with a sales gross margin of 15.27% [2] - The company is recognized as a national high-tech enterprise and has accumulated over 180 patents, which contribute to its ongoing development [1]

Overview - The core point of the announcement is the progress of the capital increase and related transactions of Shenzhen Pumen Technology Co., Ltd.'s wholly-owned subsidiary, Shenzhen Pumen Biotechnology Co., Ltd. The capital increase aims to enhance the subsidiary's financial strength and competitiveness in the consumer health sector [1][4]. Group 1: Capital Increase Details - The company approved a capital increase of 33 million RMB for its subsidiary, with the total investment from related parties reduced from 64.02 million RMB to 24.20 million RMB [1]. - The registered capital of Pumen Biotechnology will increase from 3 million RMB to 63.20 million RMB, changing the company's ownership from a wholly-owned subsidiary to a controlling subsidiary with a 56.96% stake [1][3]. Group 2: Shareholder and Management Involvement - The management is authorized to handle all matters related to the capital increase, including adjusting contributions from employee stockholding platforms and managing the partnership agreements [2]. - The capital increase involves several stakeholders, including directors, executives, and employee stockholding platforms, to create a long-term incentive system [3]. Group 3: Impact on the Company - The capital increase is expected to promote the development of the consumer health business, meet the funding needs of Pumen Biotechnology, and enhance the overall capital strength and competitiveness of the subsidiary [3]. - The transaction is structured to ensure fairness and will not adversely affect the company's financial status or independence [4].

证券代码：688389 证券简称：普门科技 公告编号：2025-057 深圳普门科技股份有限公司 关于全资子公司增资暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次增资暨关联交易事项概述 截至本公告出具日，普门生物已与各投资方签署增资相关文件，并完成本次 增资的相关工商变更登记手续，领取了深圳市市场监督管理局换发的《营业执照》， 变更后的《营业执照》相关信息如下： 企业名称：深圳普门生物科技有限公司 类型：有限责任公司 法定代表人：曾映 注册资本：6320 万人民币 成立日期：2016 年 04 月 12 日 深圳普门科技股份有限公司（以下简称"普门科技"或"公司"）于 2025 年 3 月 30 日召开第三届董事会独立董事第三次专门会议，于 2025 年 4 月 9 日召开第 三届董事会第十五次会议、第三届监事会第十四次会议，于 2025 年 5 月 7 日召开 2024 年年度股东大会，审议通过了《关于变更全资子公司增资方案暨关联交易的 议案》，同意公司变更与关联人共同对全资子公司深圳普门 ...

关于自愿披露控股子公司取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）控股子公司深圳智信生物医疗科技有 限公司（以下简称"智信生物"）于近期收到了1个广东省药品监督管理局颁发的《中华人民 共和国医疗器械注册证》，具体情况如下： 二、对公司的影响 上述取得注册证的产品适用于医院手术室、急诊室、重症监护室等科室。本次取得医疗 器械注册证，进一步丰富和完善了公司在临床医疗领域的产品矩阵，有利于提升公司的市场 竞争力，对公司未来的经营将产生积极影响。 三、风险提示 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后的实际销售 情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未来业绩的具体影响。 证券代码：688389 证券简称：普门科技 公告编号：2025-056 深圳普门科技股份有限公司 敬请投资者理性投资，注意投资风险。 特此公告。 深圳普门科技股份有限公司董事会 2025年7月4日 1 / 1 一、医疗器械注册证的具体情况 产品名 ...